Institut fuer Frauengesundheit GmbH

3 trials 2 recruiting Academic / non-commercial Merged from 2 name variants

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

1 Completed trials

1 Countries active

7 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase II: 1 Phase IV: 2

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hormone receptor positive HER2 negative breast cancer 2 Breast cancer female 2 Breast cancer 1 HER2 negative breast cancer 1 Breast cancer metastatic 1 Breast cancer male 1 Hormone receptor positive breast cancer 1

Top IMPs

All trials

3 total

TYPER Recruiting

2024-520290-12-00 Phase IV 1 country RIBOCICLIB
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Phase IV 1 country
COMPRENDO - A PHASE II OPEN LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PAT… Ended

2024-519350-37-00 Phase II 1 country

Showing 1–3 of 3 trials

← All sponsors A–Z